Study design (if review, criteria of inclusion for studies)
Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
Participants
Cystic Fibrosis - 12 Years and older (Child, Adult, Senior)
Interventions
Drug: VX-659|Drug: TEZ|Drug: IVA|Drug: TEZ/IVA
Outcome measures
Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV1)|Absolute change in CF Questionnaire-Revised (CFQ-R) respiratory domain score|Absolute change in Sweat Chloride (SwCl)|Safety and tolerability as assessed by number of subjects with adverse events (AEs) and serious adverse events (SAEs)|Observed pre-dose concentration (Ctrough) of VX-659, TEZ, M1-TEZ, and IVA